Evidence map›Paper›PMID 34686519›Full record

ReviewDiabetes2021

COVID-19-Induced New-Onset Diabetes: Trends and Technologies.

Ahmed A Metwally, Pranav Mehta, Brian S Johnson, Anvith Nagarjuna, Michael P Snyder

Open access · greenAbstract readReview
In one paragraph

Review in Diabetes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 4 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Pooled it
  5. Review
  6. Article
  7. Review
  8. Article
  9. Observational
  10. SARS-CoV-2 Main Protease Dysregulates Hepatic Insulin Signaling and Glucose Uptake: Implications for Post-COVID-19 Diabetogenesis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. COVID-19-Induced Diabetes Mellitus: Comprehensive Cellular and Molecular Mechanistic Insights.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Ahmed A MetwallyDepartment of Genetics, Stanford University, Stanford, CA ametwall@stanford.edu mpsnyder@stanford.edu.
Pranav MehtaRice University, Houston, TX.
Brian S JohnsonDepartment of Genetics, Stanford University, Stanford, CA.
Anvith NagarjunaDepartment of Genetics, Stanford University, Stanford, CA.
Michael P SnyderDepartment of Genetics, Stanford University, Stanford, CA ametwall@stanford.edu mpsnyder@stanford.edu.ORCID 0000-0003-0784-7987
Stanford University · USCairo University · EGRice University · US

Funding

Human Genome Array: Technology for Functional AnalysisP50HG002357 · NHGRI · YALE UNIVERSITY · PI SNYDER, MICHAEL P. · 2001 to 2010
$31.9M
Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Multiomic Signatures of Microbial Metabolites Following Prebiotic Fiber Supplementation Alzheimer's supplementR01AT010232 · NCCIH · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2018 to 2021
$2.0M
NCCIH NIH HHS R01 AT010232NHGRI NIH HHS P50 HG002357NIDDK NIH HHS P30 DK116074
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) global pandemic continues to spread worldwide with approximately 216 million confirmed cases and 4.49 million deaths to date. Intensive efforts are ongoing to combat this disease by suppressing viral transmission, understanding its pathogenesis, developing vaccination strategies, and identifying effective therapeutic targets. Individuals with preexisting diabetes also show higher incidence of COVID-19 illness and poorer prognosis upon infection. Likewise, an increased frequency of diabetes onset and diabetes complications has been reported in patients following COVID-19 diagnosis. COVID-19 may elevate the risk of hyperglycemia and other complications in patients with and without prior diabetes history. It is unclear whether the virus induces type 1 or type 2 diabetes or instead causes a novel atypical form of diabetes. Moreover, it remains unknown if recovering COVID-19 patients exhibit a higher risk of developing new-onset diabetes or its complications going forward. The aim of this review is to summarize what is currently known about the epidemiology and mechanisms of this bidirectional relationship between COVID-19 and diabetes. We highlight major challenges that hinder the study of COVID-19-induced new-onset of diabetes and propose a potential framework for overcoming these obstacles. We also review state-of-the-art wearables and microsampling technologies that can further study diabetes management and progression in new-onset diabetes cases. We conclude by outlining current research initiatives investigating the bidirectional relationship between COVID-19 and diabetes, some with emphasis on wearable technology.

Indexed as

SARS-CoV-2COVID-19Diabetes ComplicationsDiabetes MellitusHumans

Identifiers

PMID34686519
PMCPMC8660988
OpenAlexW3206641732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.